Fri, Mar 29, 2024
A A A
Welcome Guest
Free Trial RSS pod
Get FREE trial access to our award winning publications
Alternative Market Briefing

HealthCare Royalty Partners hits $1.83bn final close for Fund IV

Friday, January 10, 2020

Laxman Pai, Opalesque Asia:

HealthCare Royalty Partners, a global healthcare investment firm with $5.5 billion of cumulative capital commitments, announced the closing on $1.83 billion for HealthCare Royalty Partners IV (Fund IV) and affiliated entities.

Since 2003, HCR's senior professionals have invested over $3.0 billion in commercial or near-commercial stage biopharmaceutical products through the purchase of royalties, revenue interests, and credit instruments.

Fund IV, like HCR's predecessor funds, will seek to continue to provide investors with returns that are non-correlated to the broader equity or credit markets.

HCR said that many of its existing investors came back into Fund IV. It also welcomed new investors representing several of the world's leading pensions, sovereign wealth funds, financial institutions, foundations and family offices.

"The strong support from investors in the U.S., U.K., Europe, Australia, Middle East, and Africa, demonstrates the growing acceptance of pharmaceutical royalties as a supplement to traditional fixed income/credit / absolute return portfolios," it said.

"Increasing investor demand for non-correlated, yielding assets aligns well with HCR's strategy, as evidenced by the capital committed to Fund IV. HCR's regional sourcing strategy and deep bench of in-house scientists have generated strong results for HCR's predecessor fund, which we believe will continue for Fund IV," said Clarke B. Futch, Managing Partner an......................

To view our full article Click here

Previous Opalesque Exclusives                                  
Previous Other Voices                                               
Access Alternative Market Briefing

 



  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. KKR raises $6.4bn for the largest pan-Asia infrastructure fund[more]

    Laxman Pai, Opalesque Asia: The New York-based global investment firm KKR has raised a record $6.4bn for its second Asia-focused infrastructure fund, underlining investors' continued appetite for private markets. According to a media release from the alternative assets manager, the figure top

  2. Bucking the trend, top hedge fund makes plans for a second SPAC[more]

    From Institutional Investor: SPACs aren't dead. At least not to the folks at Cormorant Asset Management. The life sciences firm, whose hedge fund topped its peers in 2023, is confident it will match the success of its first blank-check company. Last week, the life sciences and biopharma speciali

  3. Benefit Street Partners closes fifth fund on $4.7 billion[more]

    Bailey McCann, Opalesque New York: Benefit Street Partners has closed its fifth flagship direct lending vehicle, BSP Debt Fund V, with $4.7 billion of investable capital across the strategy. Benefit Street invests primarily in privately originated, floating rate, senior secured loans. The fun

  4. 4 hedge fund themes that are working in 2024[more]

    From The Street: A poor earnings report from Tesla (TSLA) has not hurt the indexes on Thursday. The decline in Tesla stock, which is losing its position in the Magnificent Seven pantheon, is more than offset by strong earnings from IBM (IBM) and ServiceNow (NOW) . In addition, the much higher-t

  5. Opalesque Exclusive: A global macro fund eyes opportunities in bonds[more]

    Bailey McCann, Opalesque New York for New Managers: Munich-based ThirdYear Capital rebounded in 2023, following a tough year for global macro. The firm's flagship ART Global Macro strategy finished the year up 1